Difference between revisions of "Light-chain (AL) amyloidosis - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "")
m (Text replacement - "https://www.nejm.org/doi/full/10.1056" to "https://doi.org/10.1056")
Line 31: Line 31:
 
| style="background-color:#d3d3d3" |
 
| style="background-color:#d3d3d3" |
 
|-
 
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJM199704243361702 Kyle et al. 1997]
+
| rowspan="2" |[https://doi.org/10.1056/NEJM199704243361702 Kyle et al. 1997]
 
|rowspan=2|1982-1992
 
|rowspan=2|1982-1992
 
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
 
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
Line 47: Line 47:
 
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [http://www.amjmed.com/article/0002-9343(85)90521-2/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed]
 
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [http://www.amjmed.com/article/0002-9343(85)90521-2/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed]
 
# Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. [https://www.amjmed.com/article/0002-9343(87)90222-1/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3605135 PubMed]
 
# Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. [https://www.amjmed.com/article/0002-9343(87)90222-1/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3605135 PubMed]
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://www.nejm.org/doi/full/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed]
+
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed]
  
 
==Melphalan & Prednisone (MP) {{#subobject:946da1|Regimen=1}}==
 
==Melphalan & Prednisone (MP) {{#subobject:946da1|Regimen=1}}==
Line 72: Line 72:
 
| style="background-color:#ffffbf" |Seems not superior
 
| style="background-color:#ffffbf" |Seems not superior
 
|-
 
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJM199704243361702 Kyle et al. 1997]
+
| rowspan="2" |[https://doi.org/10.1056/NEJM199704243361702 Kyle et al. 1997]
 
|rowspan=2|1982-1992
 
|rowspan=2|1982-1992
 
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
 
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
Line 90: Line 90:
 
# Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. [http://www.bloodjournal.org/content/52/4/818.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/356916 PubMed]
 
# Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. [http://www.bloodjournal.org/content/52/4/818.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/356916 PubMed]
 
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [http://www.amjmed.com/article/0002-9343(85)90521-2/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed]
 
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [http://www.amjmed.com/article/0002-9343(85)90521-2/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed]
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://www.nejm.org/doi/full/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed]
+
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed]
  
 
[[Category:Light-chain (AL) amyloidosis regimens]]
 
[[Category:Light-chain (AL) amyloidosis regimens]]

Revision as of 13:48, 15 September 2022

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main light-chain (AL) amyloidosis regimen page to find other regimens.

2 regimens on this page
2 variants on this page


First-line therapy (including transplant ineligible)

Colchicine monotherapy

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kyle et al. 1985 NR Randomized (E-switch-ooc) MP Seems not superior
Cohen et al. 1987 1976-1983 Non-randomized
Kyle et al. 1997 1982-1992 Phase 3 (C) 1. MP Inferior OS
2. Melphalan, Prednisone, Colchicine Inferior OS

Chemotherapy

References

  1. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
  2. Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. link to original article PubMed
  3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed

Melphalan & Prednisone (MP)

MP: Melphalan & Prednisone

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kyle et al. 1978 NR Randomized (E-esc) Placebo Longer time on treatment
Kyle et al. 1985 NR Randomized (E-switch-ooc) Colchicine Seems not superior
Kyle et al. 1997 1982-1992 Phase 3 (C) 1. Colchicine Superior OS
2. Melphalan, Prednisone, Colchicine Seems not superior

Chemotherapy

Glucocorticoid therapy

References

  1. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. link to original article PubMed
  2. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
  3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed